Skin composition containing ultraviolet wavelength conversion material, hydrocarbon oil and / or linear silicone oil, and powder

Abstract

To provide a skin composition suitable for new cell activation.SOLUTION: A skin composition comprises (A) an ultraviolet wavelength converting substance and (B) hydrocarbon oil and / or linear silicone oil having a total content of 10% by weight or more and (c) powder having a total content of 0 to 65% by weight. Examples of the ultraviolet wavelength converting substance include vitamin B2 and / or a derivative thereof, phycocyanin, phycoerythrin, zinc oxide phosphor, and magnesium titanate phosphor. The skin composition also comprises (D) a UV absorber and / or (E) a UV scatterer and is useful as a sunscreen cosmetic.SELECTED DRAWING: Figure 5

Description

[Technical field]

[0001] The present invention relates to a skin composition having a cell activation effect, which contains an ultraviolet wavelength converting substance, a hydrocarbon oil and / or a linear silicone oil, and a powder. [Background technology]

[0002] UV rays are said to generate free radicals in the body, which can cause sebum oxidation and damage to cellular DNA. The harmful effects of UV rays on the skin include skin cancer, photoaging, age spots, wrinkles, and inflammation, and are undesirable from the standpoint of health and beauty. Although UV rays are used for the purpose of sterilization, considering the balance with the harmful effects of UV rays, the current situation is that the focus is on defense against UV rays rather than actively using them.

[0003] Therefore, many measures are taken to protect the skin from ultraviolet rays, such as using sunscreen, staying indoors to avoid exposure to sunlight, using hats and clothing with UV protection, and using UV-blocking film.

[0004] For example, Patent Document 11 describes a cosmetic preparation containing riboflavin butyrate, powder such as talc, and oil such as liquid paraffin, but the riboflavin butyrate is described as a yellow coloring pigment and is not an ultraviolet wavelength conversion substance for achieving a cell activation effect, and is therefore different from the present invention. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Patent No. 6424656 [Patent Document 2] Patent No. 6361416 [Patent Document 3] International Publication No. 2018 / 004006 [Patent Document 4] JP 2018-131422 A [Patent Document 5] Japanese Patent Application Publication No. 05-117127 [Patent Document 6] Patent No. 4048420 [Patent Document 7] Patent No. 4677250 [Patent Document 8] Patent No. 3303942 [Patent Document 9] JP 2017-88719 A [Patent Document 10] International Publication No. 2018 / 117117 [Patent Document 11] Japanese Patent Application Publication No. 04-054110 Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a novel skin composition which contains an ultraviolet wavelength converting substance and an oil and has a cell activation effect by utilizing ultraviolet light. [Means for solving the problem]

[0007] The present inventors have conducted extensive research into how ultraviolet light can be effectively used on the skin. As a result, they have come up with the idea of ​​a skin composition that contains an ultraviolet wavelength converting substance and oil, and has excellent cell activation effects.

[0008] The present application provides the following inventions. (1) A composition for skin comprising (A) an ultraviolet wavelength converting substance, (B) a hydrocarbon oil and / or a linear silicone oil in a total content of 10% by weight or more, and (C) a powder in a total content of 0 to 65% by weight. (2) The skin composition according to (1), wherein the ultraviolet wavelength conversion substance comprises vitamin B2 and / or a derivative thereof. (3) A composition for skin comprising (A') vitamin B2 and / or a derivative thereof, (B) a hydrocarbon oil and / or a linear silicone oil in a total content of 10% by weight or more, and (C) a powder in a total content of 0 to 65% by weight. (4) The composition for skin according to (2) or (3), wherein the total content of vitamin B2 and / or its derivatives is 0.005 to 10% by weight. (5) The composition for skin according to any one of (1) to (4), wherein the (B) hydrocarbon oil and / or linear silicone oil comprises one or more oils selected from the group consisting of isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, and methylpolysiloxane. (6) The composition for skin according to any one of (1) to (5), further comprising (D) an ultraviolet absorbing agent and / or (E) an ultraviolet scattering agent. (7) The composition for skin according to any one of (1) to (6), which is an oily composition. (8) The composition for skin according to any one of (1) to (7), which is a sunscreen cosmetic. (9) The composition for skin according to any one of (1) to (8), which exhibits a fluorescence intensity increasing effect. (10) The composition for skin according to any one of (1) to (9), which exhibits a cell activation effect. Effect of the Invention

[0009] The ultraviolet wavelength conversion substance according to the present invention is suitable for effectively utilizing ultraviolet light to activate skin cells and can exert a favorable effect on the skin, and the component composition of the skin composition according to the present invention is suitable for the ultraviolet wavelength conversion substance to convert ultraviolet light into visible light (fluorescence). Conventionally, since ultraviolet light is not good for the skin, it has been common technical knowledge in the field to take measures to avoid exposing the skin to ultraviolet light as much as possible. On the other hand, the present invention is based on the finding that the ultraviolet wavelength conversion substance exerts a favorable effect on the skin by using ultraviolet light in the opposite way to activate cells, which is very surprising. Therefore, the skin composition according to the present invention may lead to an improvement in the quality of life, such as making even those who have avoided ultraviolet light as much as possible for beauty or health reasons feel like going outside more actively. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 is a schematic diagram of Experiments 1 and 2. [Diagram 2] Figure 2 shows the cell activity upon UV irradiation using each ultraviolet ray in Experiment 1. The vertical axis shows the relative fluorescence intensity (au). [Diagram 3] Figure 3 shows the cell activity in Experiment 2 when irradiated with UV of various intensities using C-phycocyanin at various concentrations, as expressed as relative fluorescence intensity (au). [Figure 4] Figure 4 is a schematic diagram of experiment 3. [Diagram 5] Figure 5 shows the cell activity as the relative fluorescence intensity (au) when the cells, whose cell activity had been reduced in experiment 3, were irradiated with UV light using C-phycocyanin (P test). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The present invention will be described in detail below with reference to specific embodiments. However, the present invention is not limited to the following embodiments, and can be embodied in any form without departing from the spirit of the present invention.

[0012] All patent publications, published patent applications, non-patent publications, and the like cited in this disclosure are hereby incorporated by reference in their entirety into this disclosure for all purposes.

[0013] In this disclosure, when applied to a numerical value, the term "to" refers to a range of values ​​that is equal to or greater than the specified reference value and is equal to or less than the specified reference value.

[0014] (A) Ultraviolet wavelength conversion material The skin composition of the present invention contains an ultraviolet wavelength conversion substance as an active ingredient. The ultraviolet wavelength conversion substance refers to a substance that converts the wavelength of ultraviolet rays contained in incident light and emits outgoing light with a longer wavelength than the wavelength of the ultraviolet rays. The organic ultraviolet wavelength conversion substance refers to an ultraviolet wavelength conversion substance that is an organic compound, and the inorganic ultraviolet wavelength conversion substance refers to an ultraviolet wavelength conversion substance that is an inorganic compound.

[0015] The ultraviolet light may include UVA, UVB, UVC, etc. In one embodiment, the ultraviolet light is light having a peak wavelength of 200 nm to 400 nm. Also, the ultraviolet light may be included in the incident light, such as sunlight. Alternatively, the incident light may be ultraviolet light, or artificially generated ultraviolet light may be used.

[0016] The emitted light emitted by the ultraviolet wavelength conversion material has a longer wavelength than ultraviolet light, and preferably has a peak wavelength of 500 nm to 700 nm. The emitted light may have one or more peaks, for example, but is not limited to, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, 650 nm, 660 nm, 670 nm, 680 nm, 690 nm, 700 nm, or within any range of these values, or may be red light, orange light, green light, blue light, etc. In one embodiment, the ultraviolet wavelength conversion material exhibits a main wavelength of 500 nm to 700 nm when excited with excitation light of 200 nm to 400 nm.

[0017] Examples of ultraviolet wavelength conversion substances include the following: phycobiliproteins such as phycocyanin (allophycocyanin, C-phycocyanin, R-phycocyanin), phycoerythrocyanin, and phycoerythrin (B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, R-phycoerythrin); vitamin A, β-carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin Natural or synthetic ingredients such as vitamin B12, folic acid, niacin, salicylic acid, lycopene, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, flavonoids, carotenoids, quinoids, porphyrins, anthocyanins, polyphenols, etc.; Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 205 P, Yellow No. 4, Yellow No. 5, Green No. 201, Pyranine Concentrate, Dyes such as Blue No. 1, 2,4-diaminophenoxyethanol hydrochloride, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringbone Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, Red No. 104, and meta-aminophenol; phosphors doped with inorganic compounds to give them fluorescence, for example, the blue phosphor containing amorphous silica particles, cerium, phosphorus, and / or magnesium described in Japanese Patent No. 6424656 and the red phosphor containing a compound obtained by activating a mixed crystal of an alkaline earth metal sulfide and a gallium compound with europium described in Japanese Patent No. 6361416, zinc oxide phosphors described in International Publication No. 2018 / 004006, zinc oxide phosphors described in Japanese Patent Publication No. 2018-131422, inorganic phosphors described in Japanese Patent Publication No. 5-117127, and the like (hereinafter, phosphors derived from zinc oxide are referred to as "zinc oxide phosphors"). In one embodiment, the inorganic phosphor is ZnO:Zn, Zn 1+z ,ZnO 1-xThe phosphor is one or more types of phosphors selected from phosphors described in WO 2018 / 004006 in which zinc oxide, which can be expressed as follows, is doped with a sulfur-containing compound, such as zinc sulfide, zinc sulfate, and / or other sulfide salts and / or sulfate salts; magnesium titanate phosphors in which magnesium titanate, such as MgTiO3 and Mg2TiO4, is doped with manganese (hereinafter, a phosphor derived from magnesium titanate will be referred to as a "magnesium titanate phosphor"); and calcium phosphate phosphors in which calcium phosphate, such as Ca(H2PO4)2, CaHPO4, and Ca3(PO4)2, is doped with cerium.

[0018] Furthermore, the inorganic ultraviolet wavelength conversion material, which is an inorganic phosphor, may be surface-treated, for example, with a silane compound (such as octyltriethoxylane), a silicone compound, a fluorine-modified silicone compound, a fluorine compound, a higher fatty acid (such as stearic acid), a higher alcohol, a fatty acid ester, a metal soap, an amino acid, or an alkyl phosphate.

[0019] The ultraviolet wavelength conversion substance may be obtained by a method such as extraction from natural products such as animals, plants, and algae, or by an artificial method such as chemical synthesis. For example, phycobiliprotein may be prepared by extracting algae such as blue-green algae such as Spirulina platensis and red algae such as Porphyridium purpureum by a method described in, for example, Patent No. 4048420, Patent No. 4677250, Patent No. 3303942, etc. Zinc oxide phosphor may be produced by a method described in, for example, International Publication No. 2018 / 004006, JP 2018-131422, and JP 5-117127. Magnesium titanate phosphor may be produced by a method described in JP 2017-88719. Calcium phosphate phosphor may be produced by a method described in International Publication No. 2018 / 117117.

[0020] These ultraviolet wavelength conversion substances may be composed of or contain the components exemplified above, and may be used alone or in combination as long as they do not impair the wavelength conversion effect of the present invention. For example, the above phycobiliprotein or inorganic phosphor may be mixed with other ultraviolet wavelength conversion substances, such as vitamin B (vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.), to achieve a synergistic effect. However, these components are merely examples, and any substance that exhibits the wavelength conversion effect of the present invention may be used.

[0021] Vitamin B2, which is an ultraviolet wavelength converting substance, may be a derivative thereof as long as it is an ultraviolet wavelength converting substance. Examples of vitamin B2 derivatives include riboflavin acetate, riboflavin butyrate, riboflavin phosphate (which may be a salt of sodium or monodiethanolamine), flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, and riboflavin tetranicotinate, and may also be a derivative of lyxoflavin, which is a stereoisomer of riboflavin.

[0022] The content of the ultraviolet wavelength conversion substance in the cosmetic of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention, and can be appropriately determined depending on the type of ultraviolet wavelength conversion substance and the use of the cosmetic containing the ultraviolet wavelength conversion substance. For example, it can be any content within the ranges of 0.001 to 99.99% by weight, 0.001 to 10% by weight, 0.01 to 99.99% by weight, 0.01 to 10% by weight, 0.1% to 99.9% by weight, 0.1 to 10% by weight, etc.

[0023] In one embodiment of the present invention, the ultraviolet wavelength conversion substance in the composition for skin includes a zinc oxide phosphor, and the content of the zinc oxide phosphor in the composition for skin of the present invention is preferably 0.1 wt% or more, preferably 1.0 mass% or more, more preferably 1.5 wt% or more, even more preferably 2 wt% or more, and 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, or 1 to 10 wt% relative to the total composition for skin.

[0024] In one embodiment of the present invention, the ultraviolet wavelength conversion material in the composition for skin includes a magnesium titanate oxide phosphor, and the content of the magnesium titanate phosphor in the composition for skin of the present invention is preferably 0.1 wt% or more, preferably 1.0 mass% or more, more preferably 1.5 wt% or more, even more preferably 2 wt% or more, and 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.5 to 10 wt%, or 1 to 10 wt% relative to the total composition for skin.

[0025] In one embodiment of the present invention, the ultraviolet wavelength converting substance in the skin composition contains phycocyanin, and the preferred content of phycocyanin in the skin composition of the present invention is 0.00001% by weight or more, preferably 0.0001% by mass or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, based on the total weight of the skin composition. The range is 0.00001 to 99.99% by weight, 0.0001 to 99.9% by weight, 0.0001 to 50% by weight, 0.0001 to 40% by weight, 0.0001 to 30% by weight, 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.0001 to 5% by weight, 0.001 to 5% by weight, 0.01 to 5% by weight, 0.05 to 5% by weight, 0.1 to 5% by weight, 0.1 to 3% by weight, or 0.1 to 1% by weight based on the total weight of the skin composition.

[0026] In one embodiment of the present invention, the ultraviolet wavelength converting substance in the composition for skin contains vitamin B2, and the preferred content of vitamin B2 in the composition for skin of the present invention is 0.00001% by weight or more, preferably 0.0001% by weight or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, based on the total weight of the composition for skin. The range is 0.00001 to 99.99% by weight, 0.0001 to 99.9% by weight, 0.0001 to 50% by weight, 0.0001 to 40% by weight, 0.0001 to 30% by weight, 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.0001 to 5% by weight, 0.001 to 5% by weight, 0.005 to 5% by weight, 0.01 to 5% by weight, 0.01 to 1% by weight, 0.01 to 0.5% by weight, or 0.01 to 0.1% by weight based on the total weight.

[0027] Cell activation includes, but is not limited to, the promotion of metabolism and turnover of animal cells, including human cells, such as skin fibroblasts and / or keratinocytes, improving function, promoting proliferation, inhibiting oxidation, improving resistance to fatigue and external stimuli, inhibiting decline in function and activity, etc. Activation of skin cells is expected to have effects such as the prevention and improvement of wrinkles, age spots, skin aging, photoaging, etc.

[0028] The cell activation effect may be measured, for example, as in the examples, by measuring the viability, reducing ability, and proliferation of live cells using Alamar Blue, or any other method may be used, such as other dye assays, mitochondrial membrane potential-dependent dye assays, intracellular cytochrome c assays, elastase cleavage dye assays, ATP, ADE assays, glycolytic flux and oxygen consumption assays, collagen assays, photoaging assays, collagen glycation assays, assays for inflammatory substances (interleukin 1α, interleukin 8, tumor necrosis factor α, etc.), assays for skin barrier function-related proteins (corneodesmosine, sphingomyelin phosphodiesterase, filaggrin, involucrin, loricrin, transglutaminase 1, caspase 14, etc.), assays for angiogenesis regulators (VEGF-A, ANGPT1, etc.), assays for oxidation and / or skin stress-related proteins (aromatic hydrocarbon receptor repressor, cytochrome P4501B1, aromatic hydrocarbon receptor repressor, heme oxygenase 1, etc.), and hyaluronic acid assays.

[0029] The cosmetic of the present invention is suitable for exerting the function of an ultraviolet wavelength conversion substance, and is suitable for alleviating or more actively improving and recovering damage to the skin during and after ultraviolet irradiation by activating cells. More specifically, it is suitable for suppressing damage caused by collagen production and hyaluronic acid production by fibroblasts and the like, and photoaging, as well as suppressing oxidative stress in keratinocytes and the like, enhancing the barrier function, suppressing inflammatory reactions, and further suppressing collagen glycation and angiogenesis in the skin.

[0030] The fluorescence intensity can be measured, for example, as in the Examples, by forming a coating of the skin composition on the surface of a substrate, and measuring the fluorescence intensity when irradiated with ultraviolet light using a spectrofluorometer. As the substrate, a resin substrate such as polymethylmethacrylate (PMMA), nylon, or acrylic plate, or an inorganic plate such as glass or quartz can be used, and for example, a PMMA plate (also called an "S plate": see Patent No. 4453995) with a V-shaped groove on the surface can be used. The fluorescence intensity can be measured as the fluorescence value of a specific single wavelength, or as the integrated value of a specific wavelength range.

[0031] One embodiment of the composition for skin of the present invention is a composition for skin comprising (A') vitamin B2 and / or a derivative thereof, (B) a hydrocarbon oil and / or a linear silicone oil in a total content of 10% by weight or more, and (C) a powder in a total content of 0 to 65% by weight.One embodiment of the composition for skin of the present invention is a composition for skin comprising (A') vitamin B2 and / or a derivative thereof, (B) isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, methylpolysiloxane, or a combination of two or more thereof in a total content of 10% by weight or more, and (C) a powder in a total content of 0 to 65% by weight. Examples of vitamin B2 derivatives include riboflavin acetate, riboflavin butyrate, riboflavin phosphate (sodium or monodiethanolamine salt), flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, and riboflavin tetranicotinate, and may also be derivatives of lyxoflavin, a stereoisomer of riboflavin.

[0032] (B) Hydrocarbon oil and / or linear silicone oil The skin composition of the present invention contains oil components which are hydrocarbon oils and / or linear silicone oils. The oil components refer to hydrophobic substances which are components of the skin composition of the present invention and which undergo phase separation from water. The hydrocarbon oil refers to oil components having a carbon skeleton. The silicone oil refers to oily silicones having a relatively low degree of polymerization and which have siloxane bonds, and the linear silicone oil refers to linear silicone oils. The hydrocarbon oils and linear silicone oils contained in the skin composition of the present invention are preferably oil components which are liquid at room temperature.

[0033] The hydrocarbon oil is not particularly limited as long as it is one that is generally used in cosmetics, and examples thereof include liquid paraffin, tetraisobutane, hydrogenated polydecene, olefin oligomer, isododecane, isohexadecane, squalane, hydrogenated polyisobutene (liquid isoparaffin), etc. The skin composition of the present invention preferably contains liquid paraffin, tetraisobutane, hydrogenated polydecene, olefin oligomer, isododecane, isohexadecane, squalane, hydrogenated polyisobutene, and a hydrocarbon oil of a combination thereof, and preferably contains hydrogenated polydecene, isododecane, isohexadecane, and a hydrocarbon oil of a combination thereof, since this enhances the wavelength conversion function of the ultraviolet wavelength conversion material.

[0034] The linear silicone oil is not particularly limited as long as it is one that is generally used in cosmetics, and examples thereof include linear amino-modified polysiloxanes, linear polyether-modified polysiloxanes, linear alkyl-modified polysiloxanes (methylpolysiloxane, dimethylpolysiloxane (also called dimethicone), methylphenylpolysiloxane, methylhydrogenpolysiloxane, decamethyltetrasiloxane, etc.), linear fluorine-modified polysiloxanes, and linear polyoxyethylene-methylpolysiloxane copolymers. The skin composition of the present invention preferably contains decamethyltetrasiloxane and / or methylpolysiloxane silicone oils, since these enhance the wavelength conversion function of the ultraviolet wavelength conversion substance.

[0035] The oil contained in the composition for skin of the present invention is preferably a hydrocarbon oil or a linear silicone oil, and more preferably a hydrocarbon oil that is highly effective in enhancing the wavelength conversion function of the ultraviolet wavelength conversion substance. For example, the composition for skin of the present invention contains isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, methylpolysiloxane, or a combination of two or more of these. Since the composition for skin of the present invention enhances the function of the ultraviolet wavelength conversion substance of vitamin B2, it is preferable that the composition for skin of the present invention contains isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, methylpolysiloxane, or a combination of two or more of these.

[0036] The total content of the hydrocarbon oil and / or linear silicone oil contained in the composition for skin of the present invention is 3% by weight or more, 5% by weight or more, 10% by weight or more, preferably 15% by weight or more, more preferably 20% by weight or more, even more preferably 25% by weight or more, and is 80% by weight or less, preferably 60% by weight or less, more preferably 50% by weight or less, even more preferably 40% by weight or 30% by weight or less, based on the entire composition for skin. , and 10 to 80% by weight, 10 to 60% by weight, 10 to 50% by weight, 10 to 40% by weight, 10 to 30% by weight, 15 to 80% by weight, 15 to 60% by weight, 15 to 50% by weight, 15 to 40% by weight, 15 to 30% by weight, 20 to 80% by weight, 20 to 60% by weight, 20 to 50% by weight, 20 to 40% by weight, 20 to 30% by weight, 25 to 80% by weight, 25 to 60% by weight, 25 to 50% by weight, 25 to 40% by weight, or 25 to 30% by weight based on the entire skin composition.

[0037] (C) Powder The skin composition of the present invention may contain a powder. Powder refers to a solid substance that has been crushed into very fine pieces. The powder contained in the skin composition of the present invention is not particularly limited as long as it is one that is commonly used in cosmetics, and examples thereof include polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, silica, hydrophobized talc, corn starch, and hydrophobized polyurethane.

[0038] The total content of powders that can be contained in the composition for skin of the present invention is 0.01% by weight or more, preferably 0.05% by weight or more, more preferably 0.1% by weight or more, and even more preferably 0.5% by weight or more, based on the entire composition for skin, and is 70% by weight or less, 65% by weight or less, 60% by weight or less, 50% by weight or less, 40% by weight or less, 30% by weight or less, 25% by weight or less, 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, based on the entire composition for skin, and is 0 to 99.99% by weight, 0 to 70% by weight, 0 to 65% by weight, 0 to 60% by weight, 0 to 50% by weight, 0 to 40% by weight, ... Weight%, 0~30wt%, 0~20wt%, 0~15wt%, 0~10wt%, 0.1~99.9wt%, 0.1~70wt%, 0.1~65wt%, 0.1~60wt %, 0.1~50wt%, 0.1~40wt%, 0.1~30wt%, 0.1~20wt%, 0.1~15wt%, 0.1~10wt%, 0.5~70wt%, 0.5~ 65% by weight, 0.5 to 60% by weight, 0.5 to 50% by weight, 0.5 to 40% by weight, 0.5 to 30% by weight, 0.5 to 20% by weight, 0.5 to 15% by weight, 0.5 to 10% by weight, 1 to 70% by weight, 1 to 65% by weight, 1 to 60% by weight, 1 to 50% by weight, 1 to 40% by weight, 1 to 30% by weight, 1 to 20% by weight, 1 to 15% by weight, or 1 to 10% by weight.

[0039] (D) Ultraviolet absorber Ultraviolet absorbers and ultraviolet scattering agents absorb or scatter incident ultraviolet light, and are therefore thought to indirectly inhibit the function of the ultraviolet wavelength conversion substance. However, surprisingly, the skin composition of the present invention can contain an ultraviolet absorber and / or an ultraviolet scattering agent, and can exert the function of the ultraviolet wavelength conversion substance.

[0040] The ultraviolet absorbent refers to a substance that absorbs ultraviolet rays, converts them into energy such as heat or infrared rays, and then releases them. The ultraviolet absorbent that can be used in the present invention is not particularly limited as long as it does not directly impair the function of the ultraviolet wavelength conversion substance, and examples thereof include salicylic acid-based ultraviolet absorbents such as homomenthyl salicylate, ethylhexyl salicylate, homosalate, and triethanolamine salicylate; cinnamic acid-based ultraviolet absorbers such as 2-ethylhexyl paramethoxycinnamate, glyceryl di-paramethoxycinnamate mono-2-ethylhexanoate, methyl 2,5-diisopropylcinnamate, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine (hereinafter also referred to as "ethylhexyl triazone"), bis(trimethylsiloxy)silylisopentyl methyl trimethoxycinnamate, a mixture of isopropyl paramethoxycinnamate and diisopropylcinnamate, and diethanolamine p-methoxyhydrocinnamate; Benzoylmethane-based ultraviolet absorbers such as 2-phenyl-benzimidazole-5-sulfuric acid, 4-isopropyldibenzoylmethane, and 4-tert-butyl-4´-methoxydibenzoylmethane; Octocrylene, dimethoxybenzylidene dioxoimidazolidine 2-ethylhexyl propionate, 1-(3,4-dimethoxyphenyl)-4,4-dimethyl-1,3-pentanedione, cinoxate, methyl-O-aminobenzoate, 3-(4-methylbenzylidene) camphor, octyl triazone, diethylamino hydroxybenzoyl hexyl benzoate, bisethylhexyloxyphenol methoxyphenyl triazine and methylene bisbenzotriazolyl tetramethylbutylphenol; One or more selected from these may be contained in the skin composition.

[0041] The total content of the ultraviolet absorbing agent that can be contained in the composition for skin of the present invention is 0.5% by weight or more, preferably 1% by weight or more, more preferably 5% by weight or more, even more preferably 7% by weight or more, and most preferably 10% by weight or more, based on the total composition for skin in order to function as a sunscreen, and is 40% by weight or less, preferably 30% by weight or less, more preferably 25% by weight or less, and even more preferably 20% by weight or less, based on the total composition for skin in order not to absorb too much ultraviolet light contained in incident light. The total content of the ultraviolet absorbing agent that can be contained in the composition for skin of the present invention is in the range of 0.5 to 40% by weight, 1 to 40% by weight, 1 to 30% by weight, 5 to 40% by weight, 5 to 30% by weight, 5 to 25% by weight, 7 to 30% by weight, 7 to 25% by weight, 7 to 20% by weight, 10 to 30% by weight, 10 to 25% by weight, or 10 to 20% by weight.

[0042] (E) UV scattering agent The skin composition of the present invention may contain an ultraviolet scattering agent. The ultraviolet scattering agent refers to a substance that can reflect and scatter ultraviolet rays to protect the skin, etc. from ultraviolet rays. Examples of ultraviolet scattering agent materials that can be used in the present invention include titanium oxide, zinc oxide other than component (A), iron oxide, zirconium oxide, aluminum oxide, etc. In addition, examples of ultraviolet scattering agents include those made by microparticulating these materials or those made into composites. The ultraviolet scattering agent preferably contains one or more types selected from titanium oxide and zinc oxide other than component (A).

[0043] The titanium oxide and zinc oxide used as the ultraviolet scattering agent may be titanium oxide and zinc oxide that are commonly used in cosmetics. Preferably, the titanium oxide and zinc oxide have better dispersibility, for example, the surface of which is optionally treated by a known method, specifically, treated to be hydrophobic, and are contained in the skin composition.

[0044] Examples of surface treatment methods include silicone treatment with methylhydrogenpolysiloxane, methylpolysiloxane, etc., fluorine treatment with perfluoroalkyl phosphate, perfluoroalcohol, etc., amino acid treatment with N-acylglutamic acid, etc., alkylalkoxysilane treatment with octyltriethoxysilane, octyltrimethoxysilane, etc., lecithin treatment, metal soap treatment, fatty acid treatment, alkyl phosphate treatment, etc. Among these, zinc oxide with a silicone-treated surface is preferably used.

[0045] The silicone used for the surface treatment is not limited, and examples thereof include various silicone oils such as methyl polysiloxane, methyl phenyl polysiloxane, methyl hydrogen polysiloxane, methyl cyclo polysiloxane, octamethyl cyclotetrasiloxane, decamethyl cyclopentasiloxane, dodecamethyl cyclohexasiloxane, octamethyl trisiloxane, tetradecamethyl hexasiloxane, dimethyl siloxane-methyl (polyoxyethylene) siloxane-methyl (polyoxypropylene) siloxane copolymer, dimethyl siloxane-methyl (polyoxyethylene) siloxane copolymer, dimethyl siloxane-methyl (polyoxypropylene) siloxane copolymer, dimethyl siloxane-methyl cetyloxy siloxane copolymer, and dimethyl siloxane-methyl stearoxy siloxane copolymer. Methyl hydrogen polysiloxane and methyl polysiloxane are preferred.

[0046] The total content of the ultraviolet scattering agent that can be contained in the skin composition of the present invention is 0.1% by weight or more, preferably 0.5% by weight or more, more preferably 1% by weight or more, even more preferably 2% by weight or more, and most preferably 3% by weight or more, based on the total composition for skin in order to function as a sunscreen, and is 40% by weight or less, preferably 30% by weight or less, more preferably 25% by weight or less, and even more preferably 20% by weight or less, based on the total composition for skin in order not to scatter the ultraviolet rays contained in the incident light too much. The total content of the ultraviolet scattering agent that can be contained in the skin composition of the present invention is in the range of 0.1 to 40% by weight, 0.5 to 40% by weight, 0.5 to 30% by weight, 0.5 to 25% by weight, 0.5 to 20% by weight, 1 to 40% by weight, 1 to 30% by weight, 1 to 25% by weight, 1 to 20% by weight, 3 to 30% by weight, 3 to 25% by weight, or 3 to 20% by weight.

[0047] Dispersants The skin composition of the present invention may contain a dispersant. A dispersant refers to a substance that can be adsorbed to the surface of particles dispersed in an aqueous or oily phase, thereby dispersing the particles uniformly in an aqueous or oily medium. The dispersant that can be used in the present invention is not particularly limited as long as it does not impair the function of the ultraviolet wavelength conversion substance, and is preferably an oil-based dispersant. Examples of the oil-based dispersant include nonionic surfactants, cationic surfactants, anionic surfactants, silicone-based surfactants, fatty acids, etc. In the present invention, it is particularly preferable to use nonionic surfactants, silicone-based surfactants, and / or fatty acids that are commonly used in cosmetics and pharmaceuticals.

[0048] Preferred dispersing agents that may be included in the skin compositions of the present invention include PEG-10 dimethicone, bis-butyl dimethicone polyglyceryl-3, PEG-polydimethylpolysiloxane ethyl dimethicone, lauryl PEG-polydimethylpolysiloxane ethyl dimethicone, cetyl PEG / PPG-10 / dimethicone, isostearic acid, polyglyceryl-2 diisostearate, carboxydecyl trisiloxane, PEG-12 dimethicone, or polyoxyethylene sorbitan monostearate, or a combination of two or more thereof.

[0049] Preferred examples of dispersants that can be included in the skin composition of the present invention include PEG-10 dimethicone, bisbutyldimethicone polyglyceryl-3, PEG-9 polydimethylpolysiloxyethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, or carboxydecyltrisiloxane, or a combination of two or more of these, since they enhance the function of the ultraviolet wavelength conversion substance.

[0050] The content of the dispersant in the skin composition of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention, and can be appropriately determined depending on the type of ultraviolet wavelength conversion substance and the use of the skin composition containing the ultraviolet wavelength conversion substance. For example, it can be any content within the range of 0.01 to 99.99% by weight, 0.1% to 99.9% by weight, etc.

[0051] The content of the dispersant that can be contained in the composition for skin of the present invention is preferably 0.1 wt% or more, more preferably more than 0.8%, 0.9% by mass or more, more preferably 1.0% by mass or more, even more preferably 1.5 wt% or more, or 2 wt% or more, and is 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, and even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.5 to 10 wt%, 1 to 10 wt%, 1.5 to 10 wt%, 0.8 to 5 wt%, or 0.8 to 3 wt% based on the total composition for skin.

[0052] In one embodiment of the present invention, a dispersant that can be included in the composition for skin includes PEG-10 dimethicone, and the content of the dispersant in the composition for skin is 0.1 wt% or more, preferably more than 0.8%, 0.9% by mass or more, more preferably 1.0% by mass or more, even more preferably 1.5 wt% or more, or 2 wt% or more, based on the total composition for skin, and is 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, and even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.5 to 10 wt%, 1 to 10 wt%, 1.5 to 10 wt%, 0.8 to 5 wt%, or 0.8 to 3 wt% based on the total composition for skin.

[0053] In one embodiment of the present invention, the dispersing agent that can be contained in the skin composition includes a combination of one or more dispersing agents selected from the group consisting of bisbutyldimethicone polyglyceryl-3, PEG-9 polydimethylpolysiloxyethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, and carboxydecyltrisiloxane, and PEG-10 dimethicone. The content of PEG-10 dimethicone in the skin composition is 0.1% by weight or more, preferably 1.0% by weight or more, more preferably 1.5% by weight or more, even more preferably 2% by weight or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, even more preferably 5% by weight or less, and is 0.01 to 99% by weight or less, based on the entire skin composition. 0.99% by weight, 0.1 to 99.9% by weight, 0.1 to 50% by weight, 0.1 to 40% by weight, 0.1 to 30% by weight, 0.1 to 20% by weight, 0.1 to 10% by weight, 0.5 to 10% by weight, 1 to 10% by weight, 1.5 to 10% by weight, or 0.8 to 3% by weight, and the content of each dispersant in the combination is 0.1% by weight or more, preferably 1.0% by weight or more, more preferably 1.5% by weight or more, based on the total skin composition, and even more preferably It is preferably 2% by weight or more and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, and is 0.1 to 50% by weight, 0.1 to 40% by weight, 0.1 to 30% by weight, 0.1 to 20% by weight, 0.1 to 10% by weight, 0.5 to 10% by weight, 1 to 10% by weight, 1.5 to 10% by weight, 0.8 to 5% by weight, or 0.8 to 3% by weight relative to the total skin composition.

[0054] wax The skin composition of the present invention may contain a wax that is solid at room temperature. Wax refers to an oily substance with a high melting point, and examples of such waxy substances include animal fats and oils, vegetable fats and oils, and waxy hydrocarbons derived from minerals and petroleum. The wax has a melting point higher than room temperature at standard atmospheric pressure, for example, from 35°C to about 250°C, or from 40°C to about 100°C. The wax that can be contained in the skin composition of the present invention is solid or semi-solid at room temperature.

[0055] Waxes that may be included in the skin composition of the present invention are selected from waxes having hardness values ​​ranging from about 0.001 MPa (megaPa) to about 15 MPa, or such as from about 1 MPa to about 12 MPa, or such as from about 3 MPa to about 10 MPa. The hardness of the wax may be determined by any known method or device, such as by needle penetration or by use of a durometer or texturometer.

[0056] Examples of preferred waxes include, but are not limited to, beeswax, hydrogenated alkyl olive esters (commercially available under the trade name phytowax olive), carnauba wax, candelilla wax, ouricoury wax, lacquer wax, cork fiber wax or sugar cane wax, rice wax, montan wax, paraffin wax, lignite wax, microcrystalline wax, ceresin or ozokerite, palm kernel glycerides / hydrogenated palm glycerides, and hydrogenated oils such as hydrogenated castor oil or jojoba oil, sugar cane oil, oleander oil, bayberry oil, rice bran oil, soybean oil, castor oil, esparto oil, lacquer wax, hydroxyoctacosanyl hydroxystearate, Chinese wax, cetyl palmitate, lanolin, shellac and spermaceti; synthetic waxes such as those of the hydrocarbon type and polyethylene waxes obtained from the polymerization or copolymerization of ethylene, and and Fischer-Tropsch® waxes, or esters of other fatty acids, such as octacosanyl stearate, glycerides which are solid at temperatures above 35° C., silicone waxes, such as alkyl- or alkoxy dimethicones having alkyl or alkoxy chains in the range of 10 to 45 carbon atoms, poly(di)methylsiloxane esters which are solid at 30° C. and whose ester chains comprise at least 10 carbon atoms, or di(1,1,1-trimethylolpropane) tetrastearate sold or manufactured by Heterene under the name HEST® 2T-4S, and mixtures thereof.

[0057] The wax that can be contained in the skin composition of the present invention is 40% by weight or less, preferably 30% by weight or less, more preferably 25% by weight or less, and even more preferably 20% by weight or less, based on the entire skin composition, and can be used in an amount in the range of 0 to 40% by weight, 0 to 30% by weight, 0 to 25% by weight, 0 to 20% by weight, 0 to 15% by weight, 0 to 10% by weight, 5 to 40% by weight, 5 to 30% by weight, 5 to 25% by weight, 5 to 20% by weight, 5 to 15% by weight, 5 to 10% by weight, 10 to 40% by weight, 10 to 30% by weight, 10 to 25% by weight, 10 to 20% by weight, or 10 to 15% by weight based on the entire skin composition.

[0058] (Other optional ingredients) The skin composition of the present invention may contain various ingredients as appropriate within the range that does not affect the effects of the present invention. The various components include additives that can be normally incorporated into cosmetics, such as clay minerals (dimethyl distearyl ammonium hectorite, etc.), chelating agents (sodium edetate hydrate, etc.), fragrances, moisturizing agents (glycerin, dipropylene glycol, etc.), preservatives, oil phase solidifying agents (sucrose tetrastearate triacetate, dextrin palmitate, palmitic acid, (behenic acid / eicosane diacid) glyceryl, N-lauroyl L-glutamic acid dibutylamide, polyamide-8, etc.), anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, moisturizing agents, water-soluble polymers, film-forming agents such as silicone-modified polysaccharides, metal ion sequestering agents, lower alcohols, polyhydric alcohols, ester oils (diisopropyl sebacate, octyl palmitate, cetyl isooctanoate (cetyl 2-ethylhexanoate), triethylhexanoin, neopentyl glycol dicaprate, triisostearyl ester, ethylhexanoic acid ... Allanine, diisostearyl malate, PPG-3 dipivalate, di-2-ethylhexyl succinate, 2-ethylhexyl 2-ethylhexanoate, polyglyceryl-6 octacaprylate, tri(caprylic acid / capric acid)glyceryl, etc.), liquid oils and fats other than those mentioned above (avocado oil, camellia oil, macadamia nut oil, mink oil, olive oil, castor oil, jojoba oil, triglycerin, glycerin trioctanoate, etc.), higher alcohols (isostearyl alcohol Examples of the optional components include (A), oleyl alcohol, copolymers of butylene glycol and propylene glycol (e.g., PBG / PPG-9 / 1 copolymer), various extracts, sugars, amino acids, organic amines, polymer emulsions, pH adjusters, skin nutrients, vitamins other than (A) or (A'), water-soluble drugs applicable to medicines, quasi-drugs, cosmetics, etc., antioxidants, buffers, antioxidant assistants, propellants, pigments, dyes, colorants, water, acid components, alkaline components, etc. These optional components can be appropriately blended in the oil phase and the aqueous phase. Furthermore, in order to enhance the effects of the present invention, other cell activators, etc. may be contained or used in combination.

[0059] One embodiment of the composition for skin of the present invention is a water-in-oil composition. The water-in-oil composition of the present invention can be produced according to a conventional production method. Specifically, the skin composition of this embodiment is obtained by the following procedure. That is, component (B), component (C), an ultraviolet absorbing agent, an ultraviolet scattering agent, and other oily components as appropriate are mixed to prepare an oil phase, and when dispersing in the oil phase, component (A) or (A') is mixed. Next, other water-soluble components are mixed as appropriate to prepare an aqueous phase (when dispersing in the aqueous phase, component (A) or (A') is mixed as the aqueous phase). The aqueous phase is added to the oil phase and stirred to obtain a skin composition.

[0060] One embodiment of the skin composition of the present invention is a water-in-oil type composition containing a powder, such as polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, silica, talc including hydrophobized talc, starch such as corn starch, polyurethane including hydrophobized polyurethane, etc., and the water-in-oil type composition containing the powder of the present invention can be produced according to a conventional production method.

[0061] The skin composition of the present invention includes skin compositions used as makeup bases, sunscreen cosmetics such as sunscreen creams, etc. The dosage form may be, for example, emulsions, creams, solid sticks, etc.

[0062] The skin composition of the present invention can be used by applying, preferably coating, to the skin, particularly the skin excluding hair, preferably the face, body, hands, feet, etc. For example, applying, preferably coating, the skin composition of this embodiment to the skin not only protects against ultraviolet rays and suppresses adverse effects on the skin, but also activates skin cells to give the skin a natural and favorable appearance. In addition, the skin composition of the present invention can emit strong fluorescence with a small amount of phosphor, and is expected to have the effect of making the skin look brighter. EXAMPLES

[0063] The present invention will now be described in more detail with reference to examples, although the present invention is not limited thereto.

[0064] Example 1: Cell activation effects of various ultraviolet wavelength conversion substances Experiment 1-1: Preparation of ultraviolet wavelength conversion material The ultraviolet wavelength converting material was prepared as follows. (1) B-Phycoerythrin B-phycoerythrin was obtained from the extract of Porphiridium Cruentum, and its absorption spectrum had a peak wavelength at 305 nm, and its emission spectrum had peak wavelengths at 570 nm and 610 nm. (2) C-Phycocyanin C-phycocyanin was obtained from an extract of Spirulina platensis, and its absorption spectrum had a peak wavelength at 350 nm, and its emission spectrum had peak wavelengths at 640 nm and 700 nm. Linablue manufactured by DIC was used. (3) Zinc oxide phosphor Lumate G manufactured by Sakai Chemical Industry Co., Ltd. was used. Lumate G is a zinc oxide phosphor in which ZnO is doped with a sulfur-containing compound as described in International Publication No. 2018 / 004006, and its absorption spectrum had a peak wavelength at 365 nm and its emission spectrum had a peak wavelength at 510 nm. (4) Magnesium titanate phosphor Lumate R manufactured by Sakai Chemical Industry Co., Ltd. was used. Lumate R is a magnesium titanate phosphor in which MgTiO3 is doped with manganese, and its absorption spectrum has a peak wavelength at 365 nm, and its emission spectrum has a peak wavelength in the 660 to 680 nm band. The ultraviolet wavelength conversion materials (1) and (2) were dissolved in water to prepare solutions with concentrations of 1% and 5%. The ultraviolet wavelength conversion substances (3) and (4) were dispersed in alcohol to prepare 5% and 10% dispersions.

[0065] Experiment 1-2: Preparation of cell samples The cell samples were prepared as follows. 1. Human skin fibroblasts and human skin keratinocytes purchased from Kurabo were used. The cell suspension (1 mL) stored in liquid nitrogen was thawed in a water bath (37°C) until a small ice pellet remained, and then diluted with 9 mL of warm medium. 2. The dilutions were mixed gently and then transferred to T75 flasks and incubated overnight at 37°C. 3. The next day, the medium was replaced with 10 mL of fresh medium. 4. The medium was changed periodically (once every 2 days for fibroblasts, once every 2-3 days for keratinocytes) to continue cell proliferation. During this time, the cells were observed under a microscope to confirm that they were proliferating with the correct morphology. 5. When the cells reached approximately 80% confluence, they were passaged by washing the cells once with 10 mL of warm PBS, adding 5 mL of warm trypsin to a T75 flask, covering the bottom of the flask with the trypsin solution, leaving it at room temperature for 1 minute, and then aspirating. 6. The flasks were placed in a 37°C oven for 2 minutes (max) for fibroblasts and 7 minutes (max) for keratinocytes. The cells were observed under a microscope to confirm that they were small and oval. 7. The side of the T75 flask was then gently tapped to release the cells, and the cells were observed under a microscope to confirm that they were moving freely. 8. Fibroblasts were resuspended in 5mL of warm FGM (containing 10% serum) and transferred to a sterile 50mL Falcon tube. The flask was rinsed with an additional 5mL of warm FGM and added to the Falcon tube to ensure all cells were transferred. 9. The cells were centrifuged at 10,000 rpm for 5 minutes (4°C) and the supernatant was removed, taking care not to disturb the cell pellet. 10. Depending on the type of cell, fibroblasts were cultured at 2 × 10 4 cells / well (500 μL), keratinocytes were 4 × 10 4The cells were resuspended in FGM or KGM at a concentration of cells / well (500 μL) and plated in 24-well plates. 11. Seed the cells in 24-well plates and grow them by changing the medium regularly (once every 2 days for fibroblasts, once every 2-3 days for keratinocytes) until they reach 60-70% confluence (depending on the type of experiment). (Note: Fibroblasts were grown at 2 × 10 4 If the cell density is 1 × 10 cells / well, the desired confluency should be reached in 24 hours. 4 If the concentration is low, such as 100 cells / well, it will take 48 hours for the fibroblasts to reach the desired confluency. 12. 24 hours before irradiation, the medium was changed to supplement-free (for keratinocytes) or to medium containing low concentrations of serum (0.5% FCS) (for fibroblasts).

[0066] Experiment 1-3: UV irradiation 1. The solar simulator was turned on and the lamp was warmed up at least 30 minutes before irradiation. The solar simulator was set to use the UG11 filter. The UG11 filter is a filter that passes only UVB and blocks other wavelengths of light. The UV light that passed through the UG11 filter had a peak wavelength of 300 nm to 385 nm. 2. The temperature control plate was turned on and set to 33°C. 3. The cells prepared in Experiment 1-2 were washed once with warm PBS. 4. Add 0.5 mL of warmed Martinez solution (145 mM NaCl, 5.5 mM KCl, 1.2 mM MgCl2.6H2O, 1.2 mM NaH2PO4.2H2O, 7.5 mM HEPES, 1 mM CaCl2, 10 mM D-glucose) to each well. 5. As shown in Figure 1, the cell wells were placed on a plate, and 0.4 ml of the solution containing the ultraviolet wavelength conversion substances (1) to (4) prepared in Experiment 1-1 was injected into each well of the 24-well plate, and the wells containing the cells were covered. The solution of the ultraviolet wavelength conversion substance was not in direct contact with the cell solution, and UV light was irradiated onto the cell solution through the solution of the ultraviolet wavelength conversion substance. 6. The total is 100mJ / cm 2 As controls, we prepared a sample in which the cells were directly irradiated with UV light without placing a plate of the UV wavelength conversion material on the cell well, and a sample in which the cells were cultured in the dark without being irradiated with UV light. 7. After irradiation, the Martinez was replaced with warmed KGM (no supplements) or FGM (containing 0.5% FCS) and the plates were returned to the 37°C incubator.

[0067] Experiment 1-4: Measurement of cell activity After Experiments 1-3, the cells were kept in an incubator for 48 hours and the activity was measured by the following method. 1. 10% Alamar Blue was added to the medium (KGM medium without supplements or FGM medium containing 0.5% FCS) and warmed to 37°C (the solution was kept in the dark). 2. The medium in the wells was replaced with 500 μL of the above 10% Alamar Blue solution, and the plate was returned to the 37°C incubator and kept for about 3 hours. The control wells were also kept in the incubator. These solutions were kept in the dark to protect them from light. 3. After 3 hours, a 100 μL aliquot was removed and transferred to a black 96-well plate. 4. Fluorescence measurements were taken at 544 nm / 590 nm using a fluorometer (OPwave+, Ocean Photonics).

[0068] The results are shown in Figure 2. Cell activity was reduced when cells were irradiated with UV compared to the non-irradiated control. However, the activity of cells irradiated with UV through a UV wavelength conversion substance was increased for all UV wavelength conversion substances compared to the non-irradiated control. These results show that although UV irradiation reduces cell activity, the use of a UV wavelength conversion substance can suppress the reduction in cell activity.

[0069] Example 2: Effects of UV wavelength conversion material concentration and UV intensity on cell activity The cell culture was covered with a plate containing a solution containing 0%, 0.4%, and 2% C-phycocyanin as an ultraviolet wavelength conversion substance, and the irradiation intensity was 0, 10, 25, 50, 75, and 100 mJ / cm 2 The same procedure as in Experiment 1 was performed, except that UV irradiation was performed at a dose of 100 μg / ml.

[0070] The results are shown in Figure 3. When no ultraviolet wavelength conversion substance was used, the higher the UV irradiation dose, the lower the cell activity. However, when 0.4% C-phycocyanin was added, the lowering of cell activity was suppressed even with UV irradiation, and when 2% C-phycocyanin was added, cell activity was actually enhanced compared to when no UV irradiation was used. These results show that, although UV irradiation reduces cell activity, the use of an ultraviolet wavelength conversion substance not only suppresses the lowering of cell activity in a concentration-dependent manner, but also enhances cell activity.

[0071] Example 3: Restoration of cell activity decreased by UV irradiation As shown in Figure 4, the irradiation dose is 400 mJ / cm without using ultraviolet wavelength conversion material. 2 After the cell activity was temporarily reduced by UV irradiation until the UV wavelength conversion agent C-phycocyanin was added at 0%, 0.4%, and 2%, the cell culture was covered with a plate containing the solution and irradiated with 0, 10, 25, 50, 75, 100, and 200 mJ / cm. 2 The same method as in Experiment 1 was used, except that the UV irradiation was continued until the dose reached 100 μg / ml.

[0072] The results are shown in Figure 5. It can be seen that even in cells whose activity had once decreased due to UV irradiation without the use of an ultraviolet wavelength conversion substance, cellular activity was restored by UV irradiation using an ultraviolet wavelength conversion substance. Furthermore, this effect was the same even at a concentration of 0.4% C-phycocyanin as at 2%, suggesting that even at 0.4%, sufficient cell activation is achieved. On the other hand, when UV irradiation was performed without the use of an ultraviolet wavelength conversion substance, cellular activity decreased in a UV dose-dependent manner.

[0073] The above results were shown for human skin fibroblasts, but similar results were also seen for keratinocytes (data not shown). These results demonstrate that UV wavelength conversion substances not only suppress the decline in cell activity caused by UV irradiation, but also have the effect of activating cells using UV light. Activating skin cells is expected to prevent and improve wrinkles, age spots, skin aging, photoaging, etc.

[0074] From the above Examples 1 to 3, it was considered that the ultraviolet wavelength conversion substance converts the wavelength of ultraviolet light, and the emitted visible light (fluorescence with a main wavelength of 500 nm to 700 nm) activates skin cells such as fibroblasts, keratinocytes, etc. Therefore, various skin compositions containing an ultraviolet wavelength conversion substance were produced as described below, and the amount of fluorescence emitted when irradiated with ultraviolet light was evaluated.

[0075] The amount of fluorescence was measured by applying the skin care composition to an S plate (see Patent No. 4453995) at 2 mg / cm 2The coating film of the skin composition was prepared by applying ultraviolet light of a predetermined wavelength to the obtained coating film, and the fluorescence integrated value in a predetermined wavelength range was measured using a spectrofluorophotometer RF-5300PC (Shimadzu Corporation). When the ultraviolet wavelength conversion substance was zinc oxide phosphor, the coating film was irradiated with ultraviolet light of 365 nm, and the fluorescence integrated value in the range of 400-600 nm was measured in the same manner. When the ultraviolet wavelength conversion substance was magnesium titanate phosphor, the coating film was irradiated with ultraviolet light of 340 nm, and the fluorescence integrated value in the range of 550-800 nm was measured in the same manner. When the ultraviolet wavelength conversion substance was C-phycocyanin, the coating film was irradiated with ultraviolet light of 350 nm, and the fluorescence integrated value in the range of 550-800 nm was measured in the same manner. When the ultraviolet wavelength conversion substance was vitamin B2, the coating film was irradiated with ultraviolet light of 270 nm, and the fluorescence integrated value in the range of 400-750 nm was measured in the same manner.

[0076] Example 4: Function of ultraviolet wavelength conversion material in the presence of ultraviolet absorber / ultraviolet scattering agent Skin compositions (Formulation Examples U1 and U2) having the compositions shown in Table 1 were produced according to a normal production method. Formulation Examples U1 and U2 contain zinc oxide phosphor, which is an ultraviolet wavelength conversion material, and Formulation Example U2 further contains an ultraviolet absorber (octocrylene, ethylhexyl salicylate, and homosalate) and an ultraviolet scattering agent (fine particle zinc oxide). Although the fluorescence integrated value of Formulation Example U1 was 25624 and that of Formulation Example U2 was 3570, which was lower, it was found that the ultraviolet wavelength conversion material has a wavelength conversion function even in the coexistence of an ultraviolet absorber / ultraviolet scattering agent.

[0077] [Table 1]

[0078] Example 5: Effect of zinc oxide phosphor as ultraviolet wavelength conversion material Skin compositions (formulation examples G1 to G6) having the compositions shown in Table 2 were produced according to a normal manufacturing method. All formulation examples contain zinc oxide phosphor, which is an ultraviolet wavelength conversion material. The fluorescence integrated values ​​of formulation examples G1 to G6 were 669, 2230, 4273, 16116, 23515, and 43316, respectively, and it was found that zinc oxide phosphor has a wavelength conversion function in a dose-dependent manner even when included in the skin composition.

[0079] [Table 2]

[0080] Example 6: Effect of magnesium titanate phosphor as ultraviolet wavelength conversion material Skin compositions (formulation examples R1 to R5) having the compositions shown in Table 3 were produced according to a normal manufacturing method. All formulation examples contain magnesium titanate phosphor, which is an ultraviolet wavelength conversion material. The fluorescence integrated values ​​of formulation examples R1 to R5 were 4986, 7537, 5797, 5488, and 8746, respectively, and it was found that magnesium titanate phosphor has a wavelength conversion function in a dose-dependent manner even when included in a skin composition.

[0081] [Table 3]

[0082] Example 7: Effect of ultraviolet wavelength conversion substance C-phycocyanin Skin compositions (formulation examples L1 to L5) with the compositions shown in Table 4 were produced according to a conventional manufacturing method. All formulation examples contain C-phycocyanin, an ultraviolet wavelength conversion substance. The fluorescence integrated values ​​of formulation examples L1 to L5 were 6308, 11937, 9287, 5608, and 3946, respectively, indicating that C-phycocyanin has a wavelength conversion function even when included in a skin composition, and that the ultraviolet wavelength conversion effect is bell-shaped and dose-dependent, with C-phycocyanin at a concentration of 0.5% to 3% being optimal.

[0083] [Table 4]

[0084] Example 8: Effect of the dispersant PEG-10 dimethicone Skin compositions (formulation examples D1 to D4) having the compositions shown in Table 5 were produced according to a normal production method. All formulation examples contain zinc oxide phosphor, which is an ultraviolet wavelength conversion material. The fluorescence integrated values ​​of formulation examples D1 to D4 were 3570, 4015, 5657, and 6500, respectively, and it was found that the dispersant PEG-10 dimethicone dose-dependently enhances the wavelength conversion function of the zinc oxide phosphor, and that the wavelength conversion function is further enhanced by combining it with another dispersant, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone.

[0085] [Table 5]

[0086] Example 9: Effect of Combinations of Dispersants The skin compositions (formulation examples M1 to M10) having the compositions shown in Table 6 were produced according to a normal manufacturing method. All formulation examples contain zinc oxide phosphor, which is an ultraviolet wavelength conversion material. The fluorescence integrated values ​​of the formulation examples M1 to M10 are 4294, 5685, 6779, 7412, 7608, 7016, 4309, 7305, 3633, and 1531, respectively, and it was found that the wavelength conversion function of zinc oxide phosphor is enhanced by combining the dispersant PEG-10 dimethicone with bisbutyl dimethicone polyglyceryl-3, PEG-9 polydimethylpolysiloxyethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, or carboxydecyl trisiloxane, compared to PEG-10 dimethicone alone.

[0087] [Table 6]

[0088] Example 10: Effect of Powder Skin compositions (formulation examples P1 to P7) having the compositions shown in Table 7 were produced according to a normal production method. All formulation examples contain zinc oxide phosphor, which is an ultraviolet wavelength conversion material. The fluorescence integrated values ​​of formulation examples M1 to M10 were 19133, 21805, 19486, 23191, 21689, 21788, and 22552, respectively, and it was found that the inclusion of various powders in the skin composition did not suppress the wavelength conversion function of the zinc oxide phosphor, while silica powder and the like enhanced the wavelength conversion function of the zinc oxide phosphor. From this, it was thought that water-in-oil type skin compositions containing powders could also be produced as cell activators.

[0089] [Table 7]

[0090] Example 11: Effects of various oils on the UV wavelength conversion function of vitamin B2 The skin compositions (Formulation Examples O1 to O7) having the compositions shown in Table 8 were produced according to a normal manufacturing method. All of the Formulation Examples contained vitamin B2 (riboflavin) and various oils, which are ultraviolet wavelength converting substances. The fluorescence integrated values ​​of Formulation Examples O1 to O7 were 2963, 6179, 5507, 5055, 4810, 4286, and 2679, respectively, and vitamin B2 functioned as an ultraviolet wavelength converting substance. If the fluorescence integrated value of formulation example O1, which contains only PBG / PPG-9 / 1 copolymer and octyl palmitate as oils, is taken as 100%, the fluorescence integrated values ​​of formulation examples O2 to O7, which contain various other oils, are 209%, 186%, 171%, 162%, 145%, and 90%, respectively. It was found that the effect of vitamin B2 on the function of the ultraviolet wavelength conversion substance varies depending on the type of oil, and that isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, and methylpolysiloxane are particularly effective. Furthermore, the fact that isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, and methylpolysiloxane are highly effective in enhancing the ultraviolet wavelength conversion function of vitamin B2 was also observed when water-in-oil compositions were prepared by changing the dispersant (only PEG-12 dimethicone) and the UV absorber (only ethylhexyl salicylate), and it was thought that they were not significantly affected by other ingredients such as these (data not shown).

[0091] [Table 8]

[0092] Example 12: Effect on cytochrome c content In the above Examples 1 to 3, it was found that the wavelength-converted visible light enhances the reduction ability by electron acceptance from the mitochondrial respiratory chain in the AlamarBlue assay. Cytochrome c is a molecule involved in the mitochondrial electron transport system and plays an important role in the production of the NDH molecule, which is a reducing agent. Therefore, next, we investigated whether the skin composition of the present invention affects the intracellular concentration of cytochrome c in cells.

[0093] The skin composition of the present invention was applied and dispensed at 0.1 g / well onto a 24-well plate and then dried. Human skin fibroblasts (ScienCell Research Lab. #2320) were added to the 24-well plate at 1x10 5 The cells were seeded at a density of 1000 cells / well and cultured in DMEM medium (Thermo Fisher, #11965-092) for 3 days. After washing the cells with PBS, 1 mL of PBS was added. The 24-well plate containing the dried skin composition was placed on top of the 24-well plate containing the cells, and irradiated with an artificial solar light (Cerric, XC-500BF) at maximum output for 40 minutes from a distance of about 70 cm. All cell plates were placed on a heat storage material at 20°C to prevent temperature rise. After the irradiation time had elapsed, the PBS was removed, and 0.3 mL of cell extract (RIPA buffer: 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% (w / v) Sodium Deoxycholate, 0.1% (w / v) SDS, 1.0% (w / v) NP-40 substitute, 1 mM PMSF) was added, and the cells were completely dissolved by pipetting. The cell lysate was centrifuged at 10,000×g for 10 minutes at 4° C., and cytochrome c in the supernatant was measured (Proteintech Group, KE00079).

[0094] No effect was observed on the appearance of the cells before and after exposure to sunlight. The cytochrome c content in cells without the skin composition was 3782pg / mL, while the cytochrome c contents of formulation examples M4 and M5, which had high UV wavelength conversion function, were 5150pg / mL and 5448pg / mL, respectively, indicating that the content of cytochrome c in the cells was increased. From the above results, it was considered that the skin composition investigated is suitable for exerting the functions of ultraviolet wavelength conversion substances, and activates cells by increasing the concentration of cytochrome c in cells and enhancing mitochondrial activity.

[0095] As an example of a skin composition of the present invention, the following skin composition shown in Table 9 can be formulated.

[0096] [Table 9]

[0097] The above describes the embodiments of the skin composition of the present invention. However, the present invention is not limited to these, and can be modified as appropriate without departing from the spirit of the invention.

Claims

1. (A) an ultraviolet wavelength converting substance; (B) a hydrocarbon oil and / or a linear silicone oil in a total content of 15% by weight or more; and (C) a powder in a total content of 0 to 65% by weight, The ultraviolet wavelength converting substance (A) is selected from the group consisting of phycobiliprotein, β-carotene, vitamin K, vitamin B1, vitamin B2, vitamin B2 derivatives, vitamin B6, vitamin B12, folic acid, niacin, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, quinoid, porphyrins, anthocyanins, Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 205 P, Yellow No. 5, Green No. 201, Pyranine Concentrate, Blue No. 1, 2,4-diaminophenoxyethanol hydrochloride, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringbone Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, meta-aminophenol, non-aminophenol, the phosphor comprises one or more phosphors selected from the group consisting of a blue phosphor containing amorphous silica particles, cerium, phosphorus and / or magnesium, a red phosphor containing a compound obtained by activating a mixed crystal of an alkaline earth metal sulfide and a gallium compound with europium, a zinc oxide phosphor, a magnesium titanate phosphor, and a calcium phosphate phosphor, and the vitamin B2 derivative is at least one phosphor selected from the group consisting of riboflavin acetate, riboflavin butyrate, riboflavin phosphate, or a salt of riboflavin phosphate with sodium or monodiethanolamine, flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, and riboflavin tetranicotinate; The (B) hydrocarbon oil and / or linear silicone oil contains one or more selected from isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, and methylpolysiloxane, The (C) powder is at least one selected from the group consisting of polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, silica, talc, starch, and polyurethane. Composition for skin.

2. A composition comprising: (A) an ultraviolet wavelength conversion material; (B) a hydrocarbon oil and / or a linear silicone oil having a total content of 15% by weight or more; and (D) an ultraviolet absorber and / or (E) an ultraviolet scattering agent; and (C) a powder having a total content of 0 to 65% by weight, The ultraviolet wavelength converting substance (A) is selected from the group consisting of phycobiliprotein, vitamin A, β-carotene, vitamin K, vitamin B1, vitamin B2, vitamin B2 derivatives, vitamin B6, vitamin B12, folic acid, niacin, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, quinoid, porphyrins, anthocyanins, Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 205 P, Yellow No. 5, Green No. 201, Pyranine Concentrate, Blue No. 1, 2,4-diaminophenoxyethanol hydrochloride, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringbone Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, meta-aminophen the phosphor is one or more selected from the group consisting of a blue phosphor containing amorphous silica particles, cerium, phosphorus and / or magnesium, a red phosphor containing a compound obtained by activating a mixed crystal of an alkaline earth metal sulfide and a gallium compound with europium, a zinc oxide phosphor, a magnesium titanate phosphor, and a calcium phosphate phosphor, and the vitamin B2 derivative is at least one selected from the group consisting of riboflavin acetate, riboflavin butyrate, riboflavin phosphate, or a salt of riboflavin phosphate with sodium or monodiethanolamine, flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, and riboflavin tetranicotinate; The (B) hydrocarbon oil and / or linear silicone oil contains one or more selected from isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, and methylpolysiloxane, The (C) powder is at least one selected from the group consisting of polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, silica, talc, starch, and polyurethane. Composition for skin.

3. A composition comprising: (A) an ultraviolet wavelength conversion material; (B) a hydrocarbon oil and / or a linear silicone oil having a total content of 15% by weight or more; and a dispersant; and (C) a powder having a total content of 0.01 to 65% by weight, The (A) ultraviolet wavelength converting substance is selected from the group consisting of phycobiliprotein, vitamin A, vitamin K, vitamin B1, vitamin B2, vitamin B2 derivatives, vitamin B6, vitamin B12, folic acid, niacin, salicylic acid, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, carotenoid, quinoid, porphyrins, polyphenols, Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 205 P, Yellow No. 4, Yellow No. 5, Green No. 201, Pyranine Concentrate, Blue No. 1, 2,4-diaminophenoxyethanol hydrochloride, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringbone Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, and Red No.

104. the phosphor comprises one or more phosphors selected from meta-aminophenol, a blue phosphor containing amorphous silica particles, cerium, phosphorus and / or magnesium, a red phosphor containing a compound obtained by activating a mixed crystal of an alkaline earth metal sulfide and a gallium compound with europium, a zinc oxide phosphor, a magnesium titanate phosphor, and a calcium phosphate phosphor, and the vitamin B2 derivative is at least one selected from riboflavin acetate, riboflavin butyrate, riboflavin phosphate, or a salt of riboflavin phosphate with sodium or monodiethanolamine, flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, and riboflavin tetranicotinate; The (B) hydrocarbon oil and / or linear silicone oil contains one or more selected from isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, and methylpolysiloxane, the powder (C) is at least one selected from the group consisting of polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, silica, talc, starch, and polyurethane; the dispersing agent comprises PEG-10 dimethicone, bis-butyl dimethicone polyglyceryl-3, PEG-9 polydimethylsiloxyethyl dimethicone, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, or carboxydecyl trisiloxane, or a combination of two or more thereof; Composition for skin.

4. The composition for skin according to any one of claims 1 to 3, wherein the ultraviolet wavelength conversion substance comprises vitamin B2 and / or a derivative thereof.

5. (A') contains vitamin B2 and / or a derivative thereof, (B) a hydrocarbon oil and / or a linear silicone oil in a total content of 15% by weight or more, and (C) a powder in a total content of 0 to 65% by weight, the derivative is at least one selected from riboflavin acetate, riboflavin butyrate, riboflavin phosphate, or a salt of riboflavin phosphate with sodium or monodiethanolamine, flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, and riboflavin tetranicotinate; The (B) hydrocarbon oil and / or linear silicone oil contains one or more selected from isododecane, isohexadecane, hydrogenated polydecene, decamethyltetrasiloxane, and methylpolysiloxane, The powder (C) is at least one selected from the group consisting of polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, silica, talc, starch, and polyurethane. Composition for skin.

6. The composition for skin according to claim 4 or 5, wherein the total content of vitamin B2 and / or its derivatives is 0.005 to 10% by weight.

7. 7. The skin composition according to any one of claims 1, 2, and 4 to 6, further comprising a dispersing agent, the dispersing agent comprising PEG-10 dimethicone, bisbutyl dimethicone polyglyceryl-3, PEG-9 polydimethylsiloxyethyl dimethicone, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, or carboxydecyl trisiloxane, or a combination of two or more thereof.

8. The composition for skin according to any one of claims 1 and 3 to 7, further comprising (D) an ultraviolet absorbing agent and / or (E) an ultraviolet scattering agent.

9. The composition for skin according to any one of claims 1 to 8, which is an oily composition.

10. The composition for skin according to any one of claims 1 to 9, which is a sunscreen cosmetic.

11. The composition for skin according to any one of claims 1 to 10, which exhibits a fluorescence intensity enhancing effect.

12. The composition for skin according to any one of claims 1 to 11, which exhibits a cell activation effect.

Images